Correlation Between Spyre Therapeutics and ATRenew

Can any of the company-specific risk be diversified away by investing in both Spyre Therapeutics and ATRenew at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Spyre Therapeutics and ATRenew into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Spyre Therapeutics and ATRenew Inc DRC, you can compare the effects of market volatilities on Spyre Therapeutics and ATRenew and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Spyre Therapeutics with a short position of ATRenew. Check out your portfolio center. Please also check ongoing floating volatility patterns of Spyre Therapeutics and ATRenew.

Diversification Opportunities for Spyre Therapeutics and ATRenew

-0.51

Correlation Coefficient

Spyre Therapeutics  ATRenew

Excellent diversification

The 3 months correlation between Spyre and ATRenew is -0.51. Overlapping area represents the amount of risk that can be diversified away by holding Spyre Therapeutics and ATRenew Inc DRC in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ATRenew Inc DRC and Spyre Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Spyre Therapeutics are associated (or correlated) with ATRenew. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ATRenew Inc DRC has no effect on the direction of Spyre Therapeutics i.e., Spyre Therapeutics and ATRenew go up and down completely randomly.

Pair Corralation between Spyre Therapeutics and ATRenew

Given the investment horizon of 90 days Spyre Therapeutics is expected to under-perform the ATRenew. But the stock apears to be less risky and, when comparing its historical volatility, Spyre Therapeutics is 1.23 times less risky than ATRenew. The stock trades about -0.08 of its potential returns per unit of risk. The ATRenew Inc DRC is currently generating about 0.09 of returns per unit of risk over similar time horizon. If you would invest  221.00  in ATRenew Inc DRC on September 21, 2024 and sell it today you would earn a total of  54.00  from holding ATRenew Inc DRC or generate 24.43% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Spyre Therapeutics  vs.  ATRenew Inc DRC

Spyre Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Spyre Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in January 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

ATRenew Inc DRC

Risk-Adjusted Performance

7 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in ATRenew Inc DRC are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of rather uncertain basic indicators, ATRenew exhibited solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Spyre Therapeutics and ATRenew

The main advantage of trading using opposite Spyre Therapeutics and ATRenew positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Spyre Therapeutics position performs unexpectedly, ATRenew can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ATRenew will offset losses from the drop in ATRenew's long position.

The idea behind Spyre Therapeutics and ATRenew Inc DRC pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.